These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 23865725)

  • 21. Direct costs associated with initiating NPH insulin versus glargine in patients with type 2 diabetes: a retrospective database analysis.
    Lee LJ; Yu AP; Johnson SJ; Birnbaum HG; Atanasov P; Buesching DP; Jackson JA; Davidson JA
    Diabetes Res Clin Pract; 2010 Jan; 87(1):108-16. PubMed ID: 19896233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and economic outcomes among patients with diabetes mellitus initiating insulin glargine pen versus vial.
    Grabner M; Chu J; Raparla S; Quimbo R; Zhou S; Conoshenti J
    Postgrad Med; 2013 May; 125(3):204-13. PubMed ID: 23748521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of adherence and insulin delivery system on clinical and economic outcomes among patients with type 2 diabetes initiating insulin treatment.
    Ayyagari R; Wei W; Cheng D; Pan C; Signorovitch J; Wu EQ
    Value Health; 2015 Mar; 18(2):198-205. PubMed ID: 25773555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products.
    Bullano MF; Al-Zakwani IS; Fisher MD; Menditto L; Willey VJ
    Curr Med Res Opin; 2005 Feb; 21(2):291-8. PubMed ID: 15802000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adherence and persistence to a regimen of basal insulin in a pre-filled pen compared to vial/syringe in insulin-naïve patients with type 2 diabetes.
    Buysman E; Conner C; Aagren M; Bouchard J; Liu F
    Curr Med Res Opin; 2011 Sep; 27(9):1709-17. PubMed ID: 21740289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of adherence and healthcare costs of insulin device (FlexPen) versus conventional vial/syringe.
    Baser O; Bouchard J; DeLuzio T; Henk H; Aagren M
    Adv Ther; 2010 Feb; 27(2):94-104. PubMed ID: 20352392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Severe hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resources.
    Heller SR; Frier BM; Hersløv ML; Gundgaard J; Gough SC
    Diabet Med; 2016 Apr; 33(4):471-7. PubMed ID: 26179360
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs.
    Bron M; Marynchenko M; Yang H; Yu AP; Wu EQ
    Postgrad Med; 2012 Jan; 124(1):124-32. PubMed ID: 22314122
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Health economics and compliance of vials/syringes versus pen devices: a review of the evidence.
    Asche CV; Shane-McWhorter L; Raparla S
    Diabetes Technol Ther; 2010 Jun; 12 Suppl 1():S101-8. PubMed ID: 20515297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Medical resource use, disturbance of daily life and burden of hypoglycemia in insulin-treated patients with diabetes: results from a European online survey.
    Willis WD; Diago-Cabezudo JI; Madec-Hily A; Aslam A
    Expert Rev Pharmacoecon Outcomes Res; 2013 Feb; 13(1):123-30. PubMed ID: 23402452
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost, healthcare resource utilization, and adherence of individuals with diabetes using U-500 or U-100 insulin: a retrospective database analysis.
    Eby EL; Wang P; Curtis BH; Xie J; Haldane DC; Idris I; Peters AL; Hood RC; Jackson JA
    J Med Econ; 2013; 16(4):529-38. PubMed ID: 23363330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Health economics analysis of insulin aspart vs. regular human insulin in type 2 diabetes patients, based on observational real life evidence from general practices in Germany.
    Liebl A; Seitz L; Palmer AJ
    Exp Clin Endocrinol Diabetes; 2014 Oct; 122(9):517-22. PubMed ID: 25148263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overview of insulin delivery pen devices.
    Kroon L
    J Am Pharm Assoc (2003); 2009; 49(5):e118-31. PubMed ID: 19692314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of emergency department and outpatient visits for hypoglycemia in type 2 diabetes: an analysis of a large US administrative claims database.
    Simeone JC; Quilliam BJ
    Ann Pharmacother; 2012 Feb; 46(2):157-68. PubMed ID: 22234990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of non-severe hypoglycemic events on work productivity and diabetes management.
    Brod M; Christensen T; Thomsen TL; Bushnell DM
    Value Health; 2011; 14(5):665-71. PubMed ID: 21839404
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of glargine insulin delivery method (pen device versus vial/syringe) on glycemic control and patient preferences in patients with type 1 and type 2 diabetes.
    Seggelke SA; Hawkins RM; Gibbs J; Rasouli N; Wang CC; Draznin B
    Endocr Pract; 2014 Jun; 20(6):536-9. PubMed ID: 24326004
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization.
    Cooke CE; Lee HY; Tong YP; Haines ST
    Curr Med Res Opin; 2010 Jan; 26(1):231-8. PubMed ID: 19921965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The incidence and costs of hypoglycemia in type 2 diabetes.
    Quilliam BJ; Simeone JC; Ozbay AB; Kogut SJ
    Am J Manag Care; 2011 Oct; 17(10):673-80. PubMed ID: 22106460
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The burden of hypoglycemia on healthcare utilization, costs, and quality of life among type 2 diabetes mellitus patients.
    Williams SA; Shi L; Brenneman SK; Johnson JC; Wegner JC; Fonseca V
    J Diabetes Complications; 2012; 26(5):399-406. PubMed ID: 22699113
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictors of initiating rapid-acting insulin analog using vial/syringe, prefilled pen, and reusable pen devices in patients with type 2 diabetes.
    Lee LJ; Anderson J; Foster SA; Corrigan SM; Smith DM; Curkendall S
    J Diabetes Sci Technol; 2010 May; 4(3):547-57. PubMed ID: 20513319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.